検索画面
細胞材料開発室サイト

戻る 戻る
細胞番号 : 細胞名
RCB1965 : EBC-1  update : 2023/01/05
細胞特性(Comment:英)Human lung squamous cell carcinoma cell line. TKG0481 (Deposited from Tohoku Univ.).
細胞特性(日)ヒト肺扁平上皮癌由来細胞株。 TKG0481 (東北大学医用細胞資源センターからの寄託)。
細胞特性(寄託者記述:英)
細胞特性(寄託者記述:日)
使用条件(英)There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
使用条件(日)基礎的研究につきましては、使用制限はありません。商業利用や特許取得を目的とする場合は、事前に必ず理研細胞バンクに連絡をすること。
備考(英)
備考(日)
提供申込書類(英) Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
提供申込書類(日) 依頼書C-0001.pdf   同意書(非営利学術目的)C-0003.pdf   同意書(営利目的)C-0003p.pdf  
提供同意書は、使用機関の種類や目的に応じて、非営利学術目的 (C-XXXX) と営利目的 (C-XXXXp) の2種類があります。該当する提供同意書をご使用ください(詳細)。特許等の取得及び商業利用等は事前に必ず cellbank.brc@riken.jp までご連絡ください。
提供手数料 手数料とお支払いについてはこちらをご覧ください。
細胞基本情報 寄託者 Obinata, Masuo
寄託日 2004
元の細胞 TKG0481
動物種 _human < Mammals
属名 Homo
種名 sapiens
性別 Male
69 years
採取組織 lung
病名 Squamous cell carcinoma
細胞分類 cancer
入手歴 Cell Resource Center for Biomedical Research, Tohoku University(TKG0481)
細胞寿命 infinite
細胞形態 epithelial-like
Cellosaurus(Expasy) CVCL_2891
細胞培養・検査情報
寄託時情報
ロット情報
培地・試薬情報 培地・試薬一覧はこちらをご覧ください。
培養形態 Adherent cells
培地 MEM + 10% FBS
抗生物質 Free
継代方法 0.25% Trypsin
継代密度 1 : 8 split
継代・培地交換頻度 Subculture : 2 times/week
培養最適温度 37 ℃
二酸化炭素濃度 5 %
凍結培地 Medium + 10% DMSO
凍結方法 Slow freezing
マイコプラズマ (-)
アイソザイム検査 LD, NP
個体識別検査 OK
画像情報
寄託時情報
ロット情報
文献情報 Reference(英) 5件
Reference(日) 0件
利用者成果(英) 40件
利用者成果(日) 0件

トップへページトップへ
Reference(英)
3289  Yamashita J, Tashiro K, Yoneda S, Kawahara K, Shirakusa T  Local increase in polymorphonuclear leukocyte elastase is associated with tumor invasiveness in non-small cell lung cancer.  Chest  1996  109:1328-34  PubMed ID: 8625686   DOI: 10.1378/chest.109.5.1328
3287  Takigawa N, Ohnoshi T, Ueoka H, Kiura K, Moritaka T, Tabata M, Segawa Y, Shibayama T, Gemba K, Matsumura T, et al.  [In vitro comparison of podophyllotoxin analogues; etoposide, teniposide and NK 611 using human lung cancer cell lines]  Gan To Kagaku Ryoho  1993  20:473-7  PubMed ID: 8383949  
3288  Takigawa N, Ohnoshi T, Ueoka H, Horiguchi T, Kiura K, Tabata M, Segawa Y, Shibayama T, Genba K, Matsumura T, et al.  [Assessment of antitumor activity rhizoxin for human lung cancer cell lines: a potent new drug for drug-resistant lung cancer]  Gan To Kagaku Ryoho  1993  20:1221-6  PubMed ID: 8392827  
3285  Kitamura M, Shirasawa T, Mitarai T, Muramatsu T, Maruyama N  A retinoid responsive cytokine gene, MK, is preferentially expressed in the proximal tubules of the kidney and human tumor cell lines.  Am J Pathol  1993  142:425-31  PubMed ID: 8434639  
5059  Hiraki S, Miyai M, Seto T, Tamura T, Watanabe Y, Ozawa S, Ikeda H, Nakata Y, Ohnoshi T, Kimura I  Establishment of human continuous cell lines from squamous cell, adeno- and small cell carcinoma of the lung and the results of hetero-transplantation  Haigan  1982  22(1):53-8    

トップへページトップへ
Reference(日)

トップへページトップへ
利用者成果(英)
19963  Eguchi H, Yu Y, Matsunaga T, Yoshino Y, Ikari A.  Acrolein suppresses anticancer drug-induced toxicity mediated by activating claudin-1 and Nrf2 axis in a spheroid model of human lung squamous cell carcinoma cells  Toxicol Lett  2024  392:46-55  PubMed ID: 38142011   DOI: 10.1016/j.toxlet.2023.12.012
21562  Evers A, Krah S, Demir D, Gaa R, Elter D, Schroeter C, Zielonka S, Rasche N, Dotterweich J, Knuehl C, Doerner A.  Engineering hydrophobicity and manufacturability for optimized biparatopic antibody-drug conjugates targeting c-MET.  MAbs  2024  16(1):2302386  PubMed ID: 38214660   DOI: 10.1080/19420862.2024.2302386
19984  Groothuis PG, Jacobs DCH, Hermens IAT, Damming D, Berentsen K, Mattaar-Hepp E, Stokman MEM, Boekel TV, Rouwette M, van der Vleuten MAJ, Sesink A, Dijcks FA, Coumans RGE, Schouten J, Glaudemans DH, Wijk DV, Blomenröhr M, Kappers WA, Ubink R, van der Lee MMC, Dokter WHA.  Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody-Drug Conjugate  Mol Cancer Ther  2023  22(6):765-777  PubMed ID: 37042205   DOI: 10.1158/1535-7163.MCT-22-0596
21174  Alburquerque-Bejar JJ, Navajas-Chocarro P, Saigi M, Ferrero-Andres A, Morillas JM, Vilarrubi A, Gomez A, Mate JL, Munoz-Marmol AM, Romero OA, Blecua P, Davalos V, Esteller M, Pros E, Llabata P, Torres-Diz M, Esteve-Codina A, Sanchez-Cespedes M.  MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer.  Cell Rep Med  2023    PubMed ID: 37044092   DOI: 10.1016/j.xcrm.2023.101006
21436  Takatsu F, Suzawa K, Tomida S, Thu YM, Sakaguchi M, Toji T, Ohki M, Tsudaka S, Date K, Matsuda N, Iwata K, Zhu Y, Nakata K, Shien K, Yamamoto H, Nakayama A, Okazaki M, Sugimoto S, Toyooka S.  Periostin secreted by cancer-associated fibroblasts promotes cancer progression and drug resistance in non-small cell lung cancer.  J Mol Med (Berl)  2023    PubMed ID: 37831111   DOI: 10.1007/s00109-023-02384-7
21505  Sima L, Wang Z, Yu L, Hou Y, Zhao D, Luo B, Liao W, Liu X.  Discovery of LAH-1 as potent c-Met inhibitor for the treatment of non-small cell lung cancer.  J Enzyme Inhib Med Chem  2023  39(1):2286435  PubMed ID: 38078363   DOI: 10.1080/14756366.2023.2286435
16733  Stern YE, Al-Ghabkari A, Monast A, Fiset B, Aboualizadeh F, Yao Z, Stagljar I, Walsh LA, Duhamel S, Park M.  Met-HER3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cells  Cell Mol Life Sci  2022  79(3):178  PubMed ID: 35249128   DOI: 10.1007/s00018-022-04149-w
16830  Sumiya R, Terayama M, Hagiwara T, Nakata K, Sekihara K, Nagasaka S, Miyazaki H, Igari T, Yamada K, Kawamura YI.  Loss of GSTO2 contributes to cell growth and mitochondria function via the p38 signaling in lung squamous cell carcinoma  Cancer Sci  2022  113(1):195-204  PubMed ID: 34726807   DOI: 10.1111/cas.15189
13332  Hase H, Aoki M, Matsumoto K, Nakai S, Nagata T, Takeda A, Ueda K, Minami K, Kitae K, Jingushi K, Ueda Y, Yamamoto M, Furukawa T, Sato M, Tsujikawa K.  Cancer type‑SLCO1B3 promotes epithelial‑mesenchymal transition resulting in the tumour progression of non‑small cell lung cancer.  Oncol Rep  2021    PubMed ID: 33155667   DOI: 10.3892/or.2020.7839
20043  Yuan G, Flores NM, Hausmann S, Lofgren SM, Kharchenko V, Angulo-Ibanez M, Sengupta D, Lu X, Czaban I, Azhibek D, Vicent S, Fischle W, Jaremko M, Fang B, Wistuba II, Chua KF, Roth JA, Minna JD, Shao NY, Jaremko Ł, Mazur PK, Gozani O.  Elevated NSD3 histone methylation activity drives squamous cell lung cancer.  Nature  2021  590(7846):504-508  PubMed ID: 33536620   DOI: 10.1038/s41586-020-03170-y
14789  Chang A, Liu L, Ashby JM, Wu D, Chen Y, O'Neill SS, Huang S, Wang J, Wang G, Cheng D, Tan X, Petty WJ, Pasche BC, Xiang R, Zhang W, Sun P.  Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer  Cancer Res  2021  81(12):3358-3373  PubMed ID: 33853832   DOI: 10.1158/0008-5472.CAN-21-0688
15499  Kosaka A, Yajima Y, Hatayama M, Ikuta K, Sasaki T, Hirai N, Yasuda S, Nagata M, Hayashi R, Harabuchi S, Ohara K, Ohara M, Kumai T, Ishibashi K, Hirata-Nozaki Y, Nagato T, Oikawa K, Harabuchi Y, Celis E, Okumura T, Ohsaki Y, Kobayashi H, Ohkuri T.  A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapy  Cancer Sci  2021  112(7):2705-2713  PubMed ID: 34009705   DOI: 10.1111/cas.14973
16228  Joseph M. Gozgit, Melissa M. Vasbinder, Ryan P. Abo, Kaiko Kunii, Kristy G. Kuplast-Barr, Bin Gui, Alvin Z. Lu, Jennifer R. Molina, Elena Minissale, Kerren K. Swinger, Tim J. Wigle, Danielle J. Blackwell, Christina R. Majer, Yue Ren, Mario Niepel, Zacharenia A. Varsamis, Sunaina P. Nayak, Ellen Bamberg, Jan-Rung Mo, W. David Church, Ahmed S.A. Mady, Jeff Song, Luke Utley, Patricia E. Rao, Timothy J. Mitchison, Kevin W. Kuntz, Victoria M. Richon, Heike Keilhack  PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity  Cancer Cell  2021  39(9):1214-1226.e10  PubMed ID: 34375612   DOI: 10.1016/j.ccell.2021.06.018
16801  Minegishi K, Dobashi Y, Tsubochi H, Hagiwara K, Ishibashi Y, Nomura S, Nakamura R, Ohmoto Y, Endo S.  TFF-1 Functions to Suppress Multiple Phenotypes Associated with Lung Cancer Progression  Onco Targets Ther  2021  14:4761-4777  PubMed ID: 34531663   DOI: 10.2147/OTT.S322697
12073  Haruna M, Hirata M, Iwahori K, Kanazawa T, Yamamoto Y, Goto K, Kawashima A, Morimoto-Okazawa A, Funaki S, Shintani Y, Kumanogoh A, Wada H.  Docetaxel Upregulates HMGB1 Levels in Non-small Cell Lung Cancer.  Biol. Pharm. Bull.  2020    PubMed ID: 32115500   DOI: 10.1248/bpb.b19-00702
13401  Hayashi R, Nagato T, Kumai T, Ohara K, Ohara M, Ohkuri T, Hirata-Nozaki Y, Harabuchi S, Kosaka A, Nagata M, Yajima Y, Yasuda S, Oikawa K, Kono M, Kishibe K, Takahara M, Katada A, Hayashi T, Celis E, Harabuchi Y, Kobayashi H.  Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma.  Oncoimmunology  2020    PubMed ID: 33457076   DOI: 10.1080/2162402X.2020.1856545
13773  Saigusa D, Motoike IN, Saito S, Zorzi M, Aoki Y, Kitamura H, Suzuki M, Katsuoka F, Ishii H, Kinoshita K, Motohashi H, Yamamoto M.  Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites  Cancer Sci  2020  111(2):667-678  PubMed ID: 31828882   DOI: 10.1111/cas.14278
13841  Eguchi R, Wakabayashi I.  HDGF enhances VEGF‑dependent angiogenesis and FGF‑2 is a VEGF‑independent angiogenic factor in non‑small cell lung cancer  Oncol Rep  2020  44(1):14-28  PubMed ID: 32319650   DOI: 10.3892/or.2020.7580
14799  Zenke FT, Zimmermann A, Sirrenberg C, Dahmen H, Kirkin V, Pehl U, Grombacher T, Wilm C, Fuchss T, Amendt C, Vassilev LT, Blaukat A.  Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models  Mol Cancer Ther  2020  19(5):1091-1101.  PubMed ID: 32220971   DOI: 10.1158/1535-7163.MCT-19-0734
4183  Ohara K, Ohkuri T, Kumai T, Nagato T, Nozaki Y, Ishibashi K, Kosaka A, Nagata M, Harabuchi S, Ohara M, Oikawa K, Aoki N, Harabuchi Y, Celis E, Kobayashi H.  Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma.  Oncoimmunology  2018    PubMed ID: 30510853   DOI: 10.1080/2162402X.2018.1466771
4475  Iijima M, Gombodorj N, Tachibana Y, Tachibana K, Yokobori T, Honma K, Nakano T, Asao T, Kuwahara R, Aoyama K, Yasuda H, Kelly M, Kuwano H, Yamanouchi D.  Development of single nanometer-sized ultrafine oxygen bubbles to overcome the hypoxia-induced resistance to radiation therapy via the suppression of hypoxia-inducible factor‑1α.  Int. J. Oncol.  2018  52(3):679-686  PubMed ID: 29393397   DOI: 10.3892/ijo.2018.4248
14222  Horie M, Kaczkowski B, Ohshima M, Matsuzaki H, Noguchi S, Mikami Y, Lizio M, Itoh M, Kawaji H, Lassmann T, Carninci P, Hayashizaki Y, Forrest ARR, Takai D, Yamaguchi Y, Micke P, Saito A, Nagase T.  Integrative CAGE and DNA Methylation Profiling Identify Epigenetically Regulated Genes in NSCLC  Mol Cancer Res  2017  15(10):1354-1365  PubMed ID: 28698358   DOI: 10.1158/1541-7786.MCR-17-0191
14238  Ozono K, Ohishi Y, Onishi H, Nakamura K, Motoshita J, Kato M, Nakanishi R, Nakamura M, Oda Y.  Brain-derived neurotrophic factor/tropomyosin-related kinase B signaling pathway contributes to the aggressive behavior of lung squamous cell carcinoma  Lab Invest  2017  97(11):1332-1342  PubMed ID: 28604655   DOI: 10.1038/labinvest.2017.45
14945  Togayachi A, Iwaki J, Kaji H, Matsuzaki H, Kuno A, Hirao Y, Nomura M, Noguchi M, Ikehara Y, Narimatsu H.  Glycobiomarker, Fucosylated Short-Form Secretogranin III Levels Are Increased in Serum of Patients with Small Cell Lung Carcinoma.  J Proteome Res  2017  16:4495-4505  PubMed ID: 28949141   DOI: 10.1021/acs.jproteome.7b00484
9887  Ye X, Zhou Q, Matsumoto Y, Moriyama M, Kageyama S, Komatsu M, Satoh S, Tsuchida M, Saijo Y.  Inhibition of Glutaminolysis Inhibits Cell Growth via Down-regulating Mtorc1 Signaling in Lung Squamous Cell Carcinoma.  Anticancer Res.  2016  36:6021-6029  PubMed ID: 27793929   DOI: 10.21873/anticanres.11191
9977  Sellmann C, Doerner A, Knuehl C, Rasche N, Sood V, Krah S, Rhiel L, Messemer A, Wesolowski J, Schuette M, Becker S, Toleikis L, Kolmar H, Hock B.  Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates.  J. Biol. Chem.  2016  291:25106-25119  PubMed ID: 27694443   DOI: 10.1074/jbc.M116.753491
12612  Yonesaka K, Hirotani K, Kawakami H, Takeda M, Kaneda H, Sakai K, Okamoto I, Nishio K, Jänne PA, Nakagawa K.  Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib  Oncogene  2016  35(7):878-86  PubMed ID: 25961915   DOI: 10.1038/onc.2015.142
15909  Fang WT, Fan CC, Li SM, Jang TH, Lin HP, Shih NY, Chen CH, Wang TY, Huang SF, Lee AY, Liu YL, Tsai FY, Huang CT, Yang SJ, Yen LJ, Chuu CP, Chen CY, Hsiung CA, Chang JY, Wang LH, Chang IS, Jiang SS.  Downregulation of a putative tumor suppressor BMP4 by SOX2 promotes growth of lung squamous cell carcinoma  Int J Cancer  2014  135(4):809-19  PubMed ID: 24477565   DOI: 10.1002/ijc.28734
5843  Bladt F, Faden B, Friese-Hamim M, Knuehl C, Wilm C, Fittschen C, Grädler U, Meyring M, Dorsch D, Jaehrling F, Pehl U, Stieber F, Schadt O, Blaukat A.  EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.  Clin Cancer Res  2013  19(11):2941-51  PubMed ID: 23553846   DOI: 10.1158/1078-0432.CCR-12-3247
13951  Oshita H, Nishino R, Takano A, Fujitomo T, Aragaki M, Kato T, Akiyama H, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y.  RASEF is a novel diagnostic biomarker and a therapeutic target for lung cancer  Mol Cancer Res  2013  11(8):937-51  PubMed ID: 23686708   DOI: 10.1158/1541-7786.MCR-12-0685-T
17162  Kimura M, Naito H, Tojo T, Itaya-Hironaka A, Dohi Y, Yoshimura M, Nakagawara K, Takasawa S, Taniguchi S.  REG Iα gene expression is linked with the poor prognosis of lung adenocarcinoma and squamous cell carcinoma patients via discrete mechanisms  Oncol Rep  2013  30(6):2625-31  PubMed ID: 24065141   DOI: 10.3892/or.2013.2739
16553  Hayashi S, Kumai T, Matsuda Y, Aoki N, Sato K, Kimura S, Kitada M, Tateno M, Celis E, Kobayashi H.  Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer  J Transl Med  2011  9:191  PubMed ID: 22053850   DOI: 10.1186/1479-5876-9-191
16149  Kayamori K, Sakamoto K, Nakashima T, Takayanagi H, Morita K, Omura K, Nguyen ST, Miki Y, Iimura T, Himeno A, Akashi T, Yamada-Okabe H, Ogata E, Yamaguchi A.  Roles of interleukin-6 and parathyroid hormone-related peptide in osteoclast formation associated with oral cancers: significance of interleukin-6 synthesized by stromal cells in response to cancer cells  Am J Pathol  2010  176(2):968-80  PubMed ID: 20035059   DOI: 10.2353/ajpath.2010.090299
6410  Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.  Is parainfluenza virus a threatening virus for human cancer cell lines?  Hum Cell  2009  22(3):81-4  PubMed ID: 19624309   DOI: 10.1111/j.1749-0774.2009.00071.x
18311  Mitsuoka K, Miyoshi S, Kato Y, Murakami Y, Utsumi R, Kubo Y, Noda A, Nakamura Y, Nishimura S, Tsuji A.  Cancer detection using a PET tracer, 11C-glycylsarcosine, targeted to H+/peptide transporter  J Nucl Med  2008  49(4):615-22  PubMed ID: 18344442   DOI: 10.2967/jnumed.107.048231
17238  Matsuda Y, Yamamoto T, Kudo M, Kawahara K, Kawamoto M, Nakajima Y, Koizumi K, Nakazawa N, Ishiwata T, Naito Z.  Expression and roles of lumican in lung adenocarcinoma and squamous cell carcinoma  Int J Oncol  2008  33(6):1177-85  PubMed ID: 19020750  
16648  Konishi J, Yamazaki K, Yokouchi H, Shinagawa N, Iwabuchi K, Nishimura M.  The characteristics of human NKT cells in lung cancer--CD1d independent cytotoxicity against lung cancer cells by NKT cells and decreased human NKT cell response in lung cancer patients  Hum Immunol  2004  65(11):1377-88  PubMed ID: 15556688   DOI: 10.1016/j.humimm.2004.09.003
15111  Togayachi A, Akashima T, Ookubo R, Kudo T, Nishihara S, Iwasaki H, Natsume A, Mio H, Inokuchi J, Irimura T, Sasaki K, Narimatsu H.  Molecular cloning and characterization of UDP-GlcNAc:lactosylceramide beta 1,3-N-acetylglucosaminyltransferase (beta 3Gn-T5), an essential enzyme for the expression of HNK-1 and Lewis X epitopes on glycolipids  J Biol Chem  2001  276(25):22032-40  PubMed ID: 11283017   DOI: 10.1074/jbc.M011369200
1896  Bando T, Fujimura M, Kasahara K, Ueno T, Matsuda T.  Selective beta2-adrenoceptor agonist enhances sensitivity to cisplatin in non-small cell lung cancer cell line  Oncol Rep  2000  7(1):49-52  PubMed ID: 10601590   DOI: 10.3892/or.7.1.49
18075  Bando T, Fujimura M, Kasahara K, Shibata K, Shirasaki H, Heki U, Iwasa K, Ueda A, Tomikawa S, Matsuda T.  Stimulation of beta-adrenoceptor enhances sensitivity to cisplatin in non-small cell lung cancer cell lines  Int J Oncol  1997  10(6):1197-201  PubMed ID: 21533504   DOI: 10.3892/ijo.10.6.1197

トップへページトップへ
利用者成果(日)



戻る 戻る 理研トップページへ